We continue to push the boundaries of innovation with RADICAVA ORS, an orally administered option allowing patients flexibility...

Sen-Jam Pharmaceutical, an innovative life sciences company developing a portfolio of revolutionary anti-inflammatories

By launching Norstella, we’re taking the next step toward ensuring tha.t all patients have access to the therapies that they need

“The PictArray™ SARS-CoV-2 Antibody Test is a high performance, all-in-one, NP/SP COVID-19 antibody test with serological differentiation.

"With the close of this funding we will continue the journey from concept to clinical use/"

Globally, liver cancers are the fourth most common cause of cancer-related death and ranked sixth in terms of annual incidence.

Sen-Jam and KVK Tech will complete their phase II clinical trials or their oral COVID-19 drug, to have a finished product in 9-12 months.

“Cell therapies have become an essential modality in the oncology therapeutic arsenal and a priority for many biopharma companies.

Alcami serves pharmaceutical and biotech companies of all sizes providing customizable and innovative solutions

Algernon is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds.

Dizal has a portfolio of innovative therapies for the treatment of cancer, immunological diseases and chronic kidney diseases.

Bipolar disorder affects approximately 12.6 million individuals in the United States and an estimated 29 million people worldwide.

Orthox's technology, originating from Oxford University, is a revolutionary tissue scaffold based on fibroin, a tissue regenerative protein.

Third Pole has created a scalable technology that delivers nitric oxide for inhalation, instantly,on-demand, and in unlimited quantities.

More than one million users across 1,900+ customers and partners access the world's most trusted platform for clinical development and data

The global asthma therapeutics market is projected to reach $23.1 billion by 2023.

PrecisionLife is changing the way the world looks at predicting, preventing, and treating chronic disease.

KalVista Pharmaceuticals isfocused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases.

"We strongly believe that the preclinical R&D market remains largely untapped and that BenchSci can become a category-defining leader...

The MediLedger Network is the leading blockchain-powered network for automatically settling trading partner transactions in Life Sciences.

Yingli’s experience in medicinal chemistry with MD Anderson’s clinical and translational resources will advance therapeutic candiates.

RealTime provides software for clinical trial research sites, site networks, sponsors and CROs to manage complex clinical research processes

Avenge Bio is developing transformative cell-based immunotherapeutic products for the treatment of intractable solid tumors.

Oncorena's Phase I/II clinical trial of orellanine will enrol patients with advanced renal cancer already on dialysis due to renal failure.

The use of funds will include clinical program expansion and commercialization of the CAPTIS full-body embolic protection system.

Iterion Therapeutics is a venture-backed, clinical stage biotechnology company developing novel cancer therapeutics.

THE study is designed to determine the extent to which LB-100 enters recurrent GBMs and related brain tumors.

Migraine is the sixth most disabling illness in the world, which affects around a billion people worldwide.

The company's lead product utilizes a novel, non-invasive drug-device combination for outpatient treatment of rGBM.

Parthenon Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME).

Sai Life Sciences is a CRO-CDMO that enables pharma and biotech companies to accelerate the discovery and development of small molecules.

By providing reliable and accurate medical services to patients, CGBIO counts on stronger business competitiveness in digital healthcare.

This agreement marks an expansion of HTL's biotechnology beyond its work in hyaluronic acid and bio-polymer manufacturing.

Cellect Biotechnology has developed a breakthrough technology, for the selection of stem cells from any given tissue.

The financing secures funds to advance clinical development of EpiEndo’s lead compound EP395, which entered phase I clinical trials in April

Data collected on the platform has resulted in a proprietary database of over one million patients that can be specifically targeted...

“Leyden Labs is taking a really exciting approach to finding solutions for the broad-spectrum prophylactic protection against..."

“This is an important milestone for a disorder that remains largely unaddressed. Currently, there is no effective drug treatment for CNS...

he role of neratinib in gastric and gastroesophageal cancers as well as neurofibromatosis 2.

"I'm extremely pleased with the outcome of the recurrent arm of the study as it provided important safety and efficacy data to support..."

These findings represent a major breakthrough in cell transplantation, as demonstration of immune evasion and durable cell survival...

The SaNOtize treatment is based on nitric oxide a natural nanomolecule produced by the human body with proven anti-microbial properties

Iksuda’s programmes target tumours that currently have limited treatment options and high relapse rates.

“Our goal is to provide the best outcome for hereditary angioedema (HAE) patients experiencing an attack..."

Puma Biotechnology is focused on the development and commercialization of innovative products to enhance cancer care.

“Small cell lung cancer comprises approximately 15% of all lung cancers worldwide with about 30,000 new cases annually in the U.S.”

The study provides further evidence that the geko device is an effective treatment option that can improve outcomes for patients.

The incidence of head and neck cancer is increasing in the US, primarily due to rates of infection with human papillomavirus (HPV)

The trial, titled GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment), is a patient-centered, adaptive platform trial..

NRx expects to seek Emergency Use Authorization from the FDA to treat critical Covid-19 in patients suffering respiratory failure.